OUR STORY

Now recognised as the largest and most established multi-stakeholder rare disease meeting, World Orphan Drug Congress is proud to deliver another outstanding speaker line-up and a content-filled agenda that represents the whole orphan drug landscape.

With 500+ potential customers in attendance there will be opportunities to find contacts who need to find solutions to challenges around the political, commercial and scientific issues in manufacturing, clinical trials, strategy, regulation & policy, Market Access & Pricing, Science & Strategy, Pitch & Partner and Precision Medicine.

WORLD ORPHAN DRUG CONGRESS IS ALL ABOUT OPPORTUNITY

Contact Michael now at michael.hodge@terrapinn.com to secure your place

WORLD ORPHAN DRUG CONGRESS

WHY NOW?

PRICING, REIMBURSEMENT & ACCESS IS COMPLEX IN EUROPE

Pricing and access to medicines is a very challenging and complex journey, and even more so when we consider new, innovative gene therapies and rare orphan drugs. That’s why the WODC has dedicated 4 days of content on addressing these issues. This includes value evidence and perspectives from industry and patients, feedback from HTAs and payers on commercial negotiations to large European initiatives and health ministers to gain better insights on its sustainability.

ORPHAN REGULATION & POLICY

The regulatory authorities and European Commission couldn’t stress enough the importance of early dialogue and common assessment. Coupled with the European Commission’s proposal to change the orphan legislation, every stakeholder involved in orphan drugs will be impacted. Come to this congress to understand how to adapt to these new changes, gain scientific advice, a pathway to help secure accelerated approval and early consultation. Only in-person can you get real feedback and alignment between regulators, HTA and drug developers.

THE NEED FOR TRUE COLLABORATION

The rare disease community is crying out for new models to run natural history studies, registries, European Reference Networks, sustainable real-world evidence, meaningful clinical endpoints to name a few, are you inclusive in your strategy? The WODC is unique in the way we bring together all stakeholders, including patients to help challenge new partnerships and collaborations.

GENE THERAPIES

With the recent landmark EU approvals for one-time gene therapies, it’s imperative that as an industry we discuss and find solutions persisting questions around appropriate reimbursement models, patient access and scale up challenges.

PRECISION MEDICINE

How will the impact of new digital and computational tools affect rare disease diagnostics and patient care? Learn how genomics, sequencing and AI are changing the way patients access diagnostics and treatments. As we get all these precision medicine tools on our fingertips, treatments should become more and more accessible, find out how.